DaVita (DVA) Scheduled to Post Quarterly Earnings on Thursday

DaVita (NYSE:DVA) is set to issue its quarterly earnings data after the market closes on Thursday, May 2nd. Analysts expect the company to announce earnings of $1.96 per share for the quarter. DaVita has set its FY24 guidance at $8.70-9.80 EPS and its FY 2024 guidance at 8.700-9.800 EPS.Parties interested in listening to the company’s conference call can do so using this link.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, February 13th. The company reported $1.87 earnings per share for the quarter, topping the consensus estimate of $1.53 by $0.34. DaVita had a net margin of 5.70% and a return on equity of 64.42%. The firm had revenue of $3.15 billion during the quarter, compared to analysts’ expectations of $3.01 billion. During the same quarter in the prior year, the company earned $1.11 EPS. The company’s revenue was up 7.8% compared to the same quarter last year. On average, analysts expect DaVita to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

DaVita Price Performance

Shares of DVA opened at $132.75 on Thursday. The company has a 50 day moving average price of $131.63 and a 200-day moving average price of $110.00. DaVita has a fifty-two week low of $71.51 and a fifty-two week high of $141.54. The stock has a market capitalization of $11.64 billion, a PE ratio of 17.94, a PEG ratio of 1.18 and a beta of 1.04. The company has a debt-to-equity ratio of 6.65, a quick ratio of 1.13 and a current ratio of 1.19.

Analysts Set New Price Targets

A number of equities research analysts recently commented on DVA shares. Truist Financial increased their target price on shares of DaVita from $130.00 to $135.00 and gave the company a “hold” rating in a research report on Tuesday, February 20th. UBS Group increased their target price on shares of DaVita from $113.00 to $134.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th. StockNews.com cut shares of DaVita from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 16th. Barclays started coverage on shares of DaVita in a research report on Wednesday, March 6th. They set an “equal weight” rating and a $133.00 target price for the company. Finally, TheStreet raised shares of DaVita from a “c+” rating to a “b-” rating in a research report on Wednesday, February 7th. Two investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, DaVita presently has an average rating of “Moderate Buy” and an average price target of $118.50.

Insider Buying and Selling at DaVita

In other DaVita news, insider James O. Hearty sold 26,164 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the transaction, the insider now owns 20,264 shares in the company, valued at approximately $2,424,384.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Javier Rodriguez sold 67,603 shares of the stock in a transaction on Monday, February 26th. The shares were sold at an average price of $126.11, for a total value of $8,525,414.33. Following the sale, the chief executive officer now owns 488,697 shares in the company, valued at $61,629,578.67. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider James O. Hearty sold 26,164 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the completion of the sale, the insider now owns 20,264 shares in the company, valued at approximately $2,424,384.96. The disclosure for this sale can be found here. In the last quarter, insiders have sold 134,540 shares of company stock worth $16,551,071. 1.40% of the stock is owned by corporate insiders.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.